Skeletal effects of selective oestrogen receptor modulators (SERMs)

Area of Science:

• Endocrinology
• Bone Biology
• Pharmacology

Background:

• Osteoporosis is more prevalent in women, often linked to post-menopausal estrogen deficiency.
• Estrogen administration decreases bone resorption, but alternatives are sought due to side effects.
• Selective estrogen receptor modulators (SERMs) like tamoxifen and raloxifene show estrogenic effects on bone.

Purpose of the Study:

• To evaluate the efficacy of raloxifene, a SERM, in preventing bone loss and fractures in post-menopausal women.
• To compare raloxifene's anti-resorptive effects with estrogen and assess its impact on vertebral fracture incidence.

Main Methods:

• Prospective, randomized clinical trial (Multiple Outcome of Raloxifene Evaluation - MORE study).
• Two-year interim analysis involving post-menopausal women with osteoporosis receiving either raloxifene or placebo.

Main Results:

• Raloxifene demonstrated an anti-resorptive profile, acting as an agonist on bone tissue.
• Women with osteoporosis receiving raloxifene experienced a 42% reduction in vertebral fractures compared to the placebo group.
• Raloxifene's protective effect on bone is comparable to that of estrogens.

Conclusions:

• Raloxifene is an effective agent for reducing vertebral fracture risk in post-menopausal women with osteoporosis.
• SERMs like raloxifene represent a viable therapeutic option for managing estrogen deficiency-related bone loss.
• Further clinical trials confirm raloxifene's protective effects, similar to estrogen therapy.